Open AccessAn Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial
Author(s) -
Anthony Cahn,
J. Nicole Hamblin,
Jonathan Robertson,
Malcolm Begg,
Emily Jarvis,
Robert Wilson,
Gordon J. Dear,
Claudia Leemereise,
Yi Cui,
Maki Mizuma,
Mickaël Montembault,
Cedric Van Holsbeke,
Wim Vos,
Wilfried De Backer,
Jan De Backer,
Edith M. Hessel
Publication year - 2021
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s309129
Subject(s) - medicine , copd , randomized controlled trial , intensive care medicine
This study evaluated the safety and efficacy of inhaled nemiralisib, a phosphoinositide 3-kinase δ (PI3Kδ) inhibitor, in patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD).